Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 20,200 shares, a decrease of 11.8% from the December 15th total of 22,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 84,800 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

AVTX has been the topic of several recent analyst reports. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective on the stock. HC Wainwright started coverage on shares of Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating on the stock.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds have recently modified their holdings of the business. Affinity Asset Advisors LLC increased its holdings in shares of Avalo Therapeutics by 350.0% in the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after purchasing an additional 35,000 shares during the last quarter. Logos Global Management LP purchased a new position in shares of Avalo Therapeutics during the 2nd quarter worth $6,722,000. Ikarian Capital LLC boosted its position in shares of Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics in the third quarter valued at about $9,186,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Up 0.3 %

NASDAQ AVTX traded up $0.02 during mid-day trading on Friday, hitting $6.75. The stock had a trading volume of 238,024 shares, compared to its average volume of 129,572. The firm’s 50 day moving average is $9.29 and its 200 day moving average is $10.12. Avalo Therapeutics has a twelve month low of $4.00 and a twelve month high of $34.46.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.